Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies

Pharmacotherapy

Volumn 27, Issue 10, 2007, Pages 1353-1360

  Zia Amirhosseini, Parnian ^a   Hurd, David D ^c   Salfi, Margaret ^b   Cheah, Tsui Chern ^a   Aycock, Jeffrey ^a   Cesano, Alessandra ^a  

^a AMGEN INC   (United States)

^b Biostatistics   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Collapsed dose; Hematologic malignancies; Palifermin; Pharmacokinetics

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; PALIFERMIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COUGHING; DIARRHEA; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FACE EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOPOIETIC SYSTEM TUMOR; HODGKIN DISEASE; HUMAN; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL EDEMA; PROSPECTIVE STUDY; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RIGOR; SALIVATION DISORDER; SIDE EFFECT; TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; VOMITING; WHOLE BODY RADIATION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; COMBINED MODALITY THERAPY; DIARRHEA; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; FIBROBLAST GROWTH FACTOR 7; HALF-LIFE; HEMATOLOGIC NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS; WHOLE-BODY IRRADIATION;

EID: 34948842489     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1353     Document Type: Article

References (17)

1. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9.
2. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol 2000;110:292-9.
3. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993;20:1493-502.
4. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-17.
5. Bellm LA, Cunningham G, Durnell L, et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest 2002;20:793-800.
6. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004;91:69-136.
7. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 1999;27:64-71.
8. Farrell CL, Rex KL, Kaufman SA, et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999;75:609-20.
9. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase 1 trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003;21:1452-8.
10. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8.
11. Siddiqui MA, Wellington K. Palifermin: in myelotoxic therapy-induced oral mucositis. Drugs 2005;65:2139-46; discussion 2147-9.
12. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186-93.
13. Amgen Inc. Kepivance (palifermin) prescribing information. Thousand Oaks, CA; 2006.
14. Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002;54:245-51.
15. Zia-Amirhosseini P, Salfi M, Leese P, et al. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 2006;79:558-69.
16. Expert Working Group of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for industry E6 good clinical practice: consolidated guideline, April 1996. Available from http://www.fda.gov/cder/guidance/959fnl.pdf. Accessed July 23, 2007.
17. Zia-Amirhosseini P, Salfi M, Yates W, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of palifermin (PAL) (a R-HUKGF molecule). Clin Pharmacol Ther 2005;77:P17. Available from http://www.nature.com/clpt/journal/ v77/n2/abs/clpt200571a.html.